Qualitative interviews with 43 patients on capivasertib plus fulvestrant found the 4-on/3-off dosing schedule broadly acceptable, while identifying gaps in hyperglycemia recognition and willingness to use supportive medications.
Emily Mulvihill
Advertisement
Articles by Emily Mulvihill
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Understanding The Training, Credentialing Landscapes for End-of-Life Doulas
2
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
3
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
4
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
5